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Summary
Objectives: The purpose of the study was to develop a population-based simulation model of osteoarthritis (OA) in Canada that can be used to
quantify the future health and economic burden of OA under a range of scenarios for changes in the OA risk factors and treatments. In this
article we describe the overall structure of the model, sources of data, derivation of key input parameters for the epidemiological component of
the model, and preliminary validation studies.
Design: We used the Population Health Model (POHEM) platform to develop a stochastic continuous-time microsimulation model of physi-
cian-diagnosed OA. Incidence rates were calibrated to agree with administrative data for the province of British Columbia, Canada. The effect
of obesity on OA incidence and the impact of OA on health-related quality of life (HRQL) were modeled using Canadian national surveys.
Results: Incidence rates of OA in the model increase approximately linearly with age in both sexes between the ages of 50 and 80 and plateau
in the very old. In those aged 50þ, the rates are substantially higher in women. At baseline, the prevalence of OA is 11.5%, 13.6% in women
and 9.3% in men. The OA hazard ratios for obesity are 2.0 in women and 1.7 in men. The effect of OA diagnosis on HRQL, as measured by
the Health Utilities Index Mark 3 (HUI3), is to reduce it by 0.10 in women and 0.14 in men.
Conclusions: We describe the development of the ﬁrst population-based microsimulation model of OA. Strengths of this model include the use
of large population databases to derive the key parameters and the application of modern microsimulation technology. Limitations of the model
reﬂect the limitations of administrative and survey data and gaps in the epidemiological and HRQL literature.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common form of arthritis and
a leading cause of disability1,2. As the population ages, the
number of persons suffering from OA is expected to increa-
se3e6. A number of strategies have been advocated to re-
duce the burden of OA7e11. However, quantiﬁcation of the
potential impact of such strategies on future disease burden
is a complex undertaking. The effects of important risk fac-
tors for OA, such as age and overweight/obesity, are non-
linear and the distribution of both factors in the population
is changing2,12,13. Similarly, extrapolating the beneﬁts and
side-effects of interventions from randomized trials to*Address correspondence and reprint requests to: J. A. Kopec,
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303a population setting is not straightforward as one has to
consider the existing treatment patterns, heterogeneity of
effects, as well as changes in the demographic structure
of the population14. Because of such complexities, standard
economic and policy analyses of OA burden typically make
simplifying assumptions about the population under study
and the impact of interventions over time15,16.
Simulation modeling of disease processes in a population
can inform health policy and has consequently become in-
creasingly accepted and adopted17. Recent developments in
modeling technology include microsimulation, continuous-
time models, and advances in model calibration18. An impor-
tant distinction is between macrolevel (group-based) models
and microsimulation. In macrolevel models, groups of individ-
uals move through several stages based on transition proba-
bilities and the summary measures of interest are calculated.
In contrast,microsimulationmodels simulate individual life his-
tories, with the timing of events determined stochastically19.
The main advantages of microsimulation include a potentially
inﬁnite number of events and stages in disease process that
304 J. A. Kopec et al.: A microsimulation model of osteoarthritiscan be modeled and ﬂexibility in deﬁning input populations,
merging multiple data sources, taking into account heteroge-
neity of effects, and implementing changes in the model18e21.
Thanks toadramaticprogress incomputer technology it isnow
possible to perform the calculations needed to simulate mil-
lions of individual life histories18. Complex population-level
processes can be described by a series of relatively simple
equations and probabilistic parameters at the level of the indi-
vidual. The model integrates such individual-level data and
translates them into projections of disease burden in the pop-
ulation. By changing the input parameters, such as the distri-
bution of disease risk factors and comparing the likely
outcomes, it is possible to evaluate various interventions in
terms of their expected impact on disease incidence, preva-
lence, mortality, quality-adjusted life years (QALYs), and
costs17e19. Although simulationmodels have been used in ar-
thritis research for cost-effectiveness and decision analys-
es22e27, none of these models has been based on
generating individual life histories in a population or included
a primary prevention component.
The purpose of the study was to develop a simulation
model of OA in a Canadian population that can be used
to quantify the future health and economic burden of OA un-
der a range of plausible scenarios for changes in the risk
factors and treatments. In this article we provide an over-
view of the model development process, with a focus on
OA incidence and its impact on quality of life. Modeling of
the impact of OA treatment (both surgical and non-surgical)
and economic aspects of OA will be presented in separateAge & Sex
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Fig. 1. POHEM-OA: Schematic representation of the key relationships anpublications. The following stages in model development
are described: (1) conceptualization of the disease; (2) im-
plementation of a computer simulation program; (3) deriva-
tion of the model parameters; and (4) model calibration and
validation. The key assumptions and limitations of the
model are discussed.
MethodsCONCEPTUAL FRAMEWORKPOHEM-OA is a population-based simulation model. The disease is de-
ﬁned as physician-diagnosed OA of any site, as opposed to radiographic
or clinical OA. Population-level data on radiographically or clinically deﬁned
OA of speciﬁc joints are not available in Canada. Furthermore, this is an in-
cidence-driven model e the key parameter is OA incidence (hazard) rate.
The incidence rate is modeled as a function of established risk factors for
OA, allowing for non-linear dose-response relationships and effect modiﬁca-
tion. Trends in OA incidence are determined by changes in the distribution of
risk factors in the population over time. The burden of OA can be expressed
in terms of the number of cases and impact on health-related quality of life
(HRQL). The key components of the model and relationships between
them are presented in Fig. 1. Main model parameters, methods of derivation,
and data sources are listed in Table I. Baseline population data and technical
details are provided in the Appendix.SIMULATION PLATFORMSimulations are performed using the Population Health Model (POHEM)
platform28. POHEM is a generic, continuous-time microsimulation environ-
ment developed at Statistics Canada29. The unit of simulation is the individ-
ual and the events can occur at arbitrarily small time intervals. This modeling
approach differs from group-based methods of modeling proportions andBMI
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Table I
Key POHEM-OA parameters, data sources, and methods of derivation
Parameter Source and method of derivation
Distribution of baseline population by age, sex,
province, education, income, BMI and HUI3
Observed in CCHS (2001)
Baseline prevalence of OA by age and sex Obtained as the ﬁnal stable prevalence from a simulation of the Canadian
population over a 50-year time horizon, under constant age/sex-speciﬁc,
BCLHD-based incidence rates.
Mortality rates by age and sex over time Based on mortality data and using Statistics Canada projections
of mortality for Canada.
Baseline incidence rates of OA by age and sex Obtained from BCLHD. OA was deﬁned as at least two visits to a health
professional within 2 years or one hospitalization with the
International Classiﬁcation of Diseases, Ninth Revision (ICD-9) code 715.
Incident cases were identiﬁed after excluding prevalent cases,
using a 12-year run-in period.
Reference incidence rates of OA
(for persons with normal BMI) by age and sex
Obtained numerically using an iterative algorithm (calibration).
These rates are based on the incidence rates from BCLHD and
the distribution of BMI levels in the CCHS population, within age/sex groups.
Effect of BMI on incident OA, by sex Obtained from a survival regression model, separately for men and women,
and adjusted for age. BMI was treated as a categorical variable
(<18.5, 18.5e25, 25e30, 30þ). The model is based on longitudinal
data from the NPHS (2000e2002).
Effects of OA, age, sex, and BMI on HUI3 Obtained from a tobit regression model including age, sex, BMI, and
OA status (with interactions as required). The model is based on
cross-sectional data from the CCHS (2001).
Effects of prior BMI, sex, education,
income, and region on change in BMI
Obtained from a series of linear regression models for groups
deﬁned by BMI and age categories. The models are based on
longitudinal data from the NPHS (1996e2004).
HUI3¼Health Utilities Index Mark 3.
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speciﬁed states30,31. POHEM generates individual life trajectories within
a large population representative of Canada, one individual at a time, until
death. The stochastic nature of POHEM means that replicated lives with
identical initial conditions have different life trajectories, because they have
a different stream of random numbers used in their decision path. POHEM
has been validated and used to assess the impact of prevention strategies,
treatments, and cost of care in breast, lung, and colorectal cancer32e38.PARAMETERS AND SOURCES OF DATAAge and gender
POHEM-OA uses the 2001 Canadian Community Health Survey (CCHS)
sample as the baseline population39. The CCHS is a cross-sectional survey
conducted every 2 years, with a total national sample of 130,000. The CCHS
target population includes persons age 12þ, living in households in the 10 Ca-
nadian provinces, with the exception of Indian reserves, military bases, and
some remote northern areas. POHEM-OA includes subjects 18 years of age
or older. Each subject from the CCHS sample is replicated at time of initializa-
tion to reﬂect its survey sampleweight. Consequently, approximately 25million
individual lives, reﬂecting the non-institutionalized adult Canadian population,
are simulated in a single run. Since POHEM-OA simulates a dynamic popula-
tion, subjects are removed from the population as a result of death and new
subjects are added to the population by aging into it (on their 18th birthday).
To simulate these events, death and birth rates by age and sex were obtained
from the national vital statistics and census databases routinely used byStatis-
tics Canada for demographic projections40.
Body mass index (BMI)
At the population level, the most important modiﬁable risk factor for OA is
BMI2,12,41. The distribution of BMI in the baseline population was obtained di-
rectly from the CCHS, based on the formula BMI¼weight/height2 (Table I).
Individual BMI trajectories were simulated using a regression model based
on longitudinal data from the National Population Health Survey (NPHS) in
Canada42. The NPHS started in 1994 with a random household population
sample of about 20,000, with a sampling frame similar to that of the
CCHS. These subjects are followed every 2 years43. The model to simulate
BMI used data from 1996 to 2004 and included age, sex, province of resi-
dence, education, income, and prior BMI.OA incidence
In POHEM-OA, OA incidence at the start of simulation is adjusted to re-
ﬂect the incidence of physician-diagnosed OA in Canada. This adjustment,
referred to as calibration, uses age/sex-speciﬁc incidence rates for 2003/4
(the last year for which data were available), derived from the British Colum-
bia Linked Health Database (BCLHD) (Table I). The BCLHD is a well-estab-
lished administrative database in the province of British Columbia, Canada
that has been used extensively for research purposes44. It contains data
on physician billings in the publicly funded health care system covering
>95% of the population. The methodology for estimating incidence rates
of OA from administrative data has been described elsewhere45. The deﬁni-
tion of OA required either two physician visits within 2 years of each other or
one hospitalization with the ICD-9 code 715 (Osteoathrosis and allied disor-
ders) or the corresponding ICD-10 codes. To obtain incidence rates for Can-
ada, age/sex-speciﬁc BC rates were applied to the age/sex distribution of the
Canadian population.
OA prevalence
As not all individuals with diagnosed OA seek regular medical care for
their condition46, age/sex-speciﬁc prevalence proportions of OA from an ad-
ministrative database may underestimate the true prevalence, particularly if
the run-in time is too short45. To ensure consistency between incidence
and prevalence data, we simulated OA prevalence in the Canadian popula-
tion over a long period of time (up to 50 years) while keeping the incidence
rates constant at the most recent level. The age/sex-speciﬁc prevalence pro-
portions obtained from this simulation were applied to the baseline CCHS
population to obtain the distribution of OA at baseline47.
Effect of BMI
When simulating the occurrence of OA in individuals, the age/sex-spe-
ciﬁc hazard rates are modiﬁed according to the person’s BMI. The effect
of BMI on OA risk has been estimated using longitudinal data from the
two cycles of the NPHS (2000 and 2002) that asked the question on any
self-reported physician-diagnosed OA and were available for analysis. To
this end, we have ﬁt a multivariable survival regression model. The effect
of BMI is expressed as hazard ratios for underweight (BMI< 18.5), over-
weight (BMI 25.0e29.9) and obesity (BMI 30þ), compared to normal BMI
(18.5e24.9). The effects were estimated separately for males and females
and adjusted for age (Table I).
Table II
Age/sex-specific incidence rates of physician-diagnosed OA per
1000 person-years in British Columbia, Canada
Age range Men Women
20e24 0.54 0.63
25e29 0.91 0.82
30e34 1.54 1.55
35e39 2.55 2.59
40e44 4.05 4.09
45e49 6.22 7.32
50e54 8.10 12.04
55e59 11.36 18.21
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POHEM-OA uses the Health Utilities Index Mark 3 (HUI3) as a measure
of HRQL. HUI3 is based on eight attributes (vision, hearing, speech, ambu-
lation, dexterity, emotional function, cognitive function, and pain)48. The attri-
butes are combined into an overall index, ranging from 0.36 to 1, using
a multi-attribute utility theory model based on societal preferences. There-
fore, HUI3 can be employed to estimate QALY. The initial distribution of
HUI3 in POHEM-OA is obtained directly from the CCHS. Individual HUI3 tra-
jectories were simulated with a tobit regression model (accounting for the
skewed distribution of HUI3 scores) that included age, gender, BMI, and
OA status49. The model was derived from the 2001 cycle of the CCHS
(Table I). Model ﬁt was evaluated by the likelihood ratio test and a com-
parison of the scale parameter, which estimates the standard deviation of
the normal error term, between the reduced and saturated model.60e64 14.66 22.48
65e69 17.59 26.93
70e74 20.30 31.00MODEL CALIBRATION AND VALIDATION
75e79 23.26 34.47
80e84 24.22 33.77
85e89 25.77 33.42
90þ 25.54 31.55
Incident OA was deﬁned as at least two visits to a physician with
ICD-9 code 715 within 1e730 days or one hospital diagnosis with
a diagnostic code 715 in a person not diagnosed with OA in the pre-
vious 12 years. Rates are calculated for the period from April 1st
2003 to March 31st, 2004, based on data from the BC Linked
Health Database.The population modeled by POHEM-OA reﬂects the Canadian adult
household population surveyed by the CCHS. As the model simulates indi-
vidual life histories, the risk of OA is inﬂuenced by individual BMI values ac-
cording to the relative risk derived from the NPHS. In order that the
aggregated age/sex-speciﬁc incidence rates in the simulated population cor-
respond to the observed population rates in administrative data, given the
population distribution of BMI, the age/sex-speciﬁc rates for the reference
BMI category need to be estimated. This was achieved through model cali-
bration, whereby the reference rates were iteratively adjusted using numer-
ical methods until the simulated and observed incidence rates (within age/
sex categories) agreed18,19.
The population distribution by age from 2001 to 2007 in POHEM-OA has
been compared to the actual Canadian population-based on estimates from
the 2001 and 2006 censuses. To validate the simulated OA frequency, we
compared the incidence and prevalence of OA in POHEM-OA with self-re-
ported incidence of arthritis and rheumatism in the NPHS, self-reported OA
prevalence in the CCHS and BCLHD, and clinical and radiographic OA inci-
dence and prevalence from the literature45,47,50,51. We also assessed the ef-
fects of OA deﬁnition and run-in time on the incidence and prevalence of OA
in administrative data45. In addition, we have estimated the sensitivity and
speciﬁcity of the administrative deﬁnition of OA by linking the BCLHD to
a population-based cohort study of 171 subjects with extensive clinical and
radiographic data52. Finally, our model for predicting HUI3 in the general
population has been validated by comparing the predicted and observed
HUI3 scores in a different cycle of the CCHS.Results
POHEM-OA has a large number of parameters, including
descriptive parameters, such as age and sex distribution at
baseline, birth and death rates by age, sex, and year, edu-
cation and income distribution, age/sex-speciﬁc OA preva-
lence proportions at baseline, age/sex-speciﬁc OA
incidence rates, and other parameters. In this article we dis-
cuss the key input parameters related to the frequency and
health impact of OA (Table I).0
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Fig. 2. Comparisons of POHEM-based and Census-based popula-
tion counts for Canada in 2007, by age group.In Fig. 2, we compare the simulated age distribution in
POHEM-OA in 2007 with the distribution estimated from
the 2006 census. The data show a nearly perfect corre-
spondence between the two datasets. Minor discrepancies
are mainly due to the exclusion of the institutionalized pop-
ulations in the CCHS and differences between the weights
developed for the CCHS in 2001 and the revised census
estimates.
Age/sex-speciﬁc incidence rates of physician-diagnosed
OA in POHEM-OA are presented in Table II. The rates in-
crease approximately linearly with age in both sexes be-
tween the ages of 50 and 80 and plateau in the very old.
In persons 50þ, women have substantially higher rates
than men, with the male-to-female ratio between 0.6 and
0.7 in most age groups. The baseline prevalence of OA
generated from the POHEM-OA simulation is 11.5%,
13.6% in women and 9.3% in men.
In Table III we provide the age-adjusted OA hazard ratios
for the different BMI categories, separately for men and
women. Since the main purpose of this analysis was to pro-
vide the input parameters for the simulation model, conﬁ-
dence intervals are not reported. The effect of BMI is
stronger in women, with the hazard ratios of 1.76 and
2.03 for BMI 25e29.9 and 30þ, respectively, compared to
normal weight (BMI between 18.5 and 24.9). The corre-
sponding hazard ratios for men are 1.07 and 1.69. Rates
are decreased for men and women with BMI< 18.5 (in
our sample there were no cases of OA among men with
BMI< 18.5).Table III
Effect of BMI on OA incidence in the NPHS in Canada
(2000e2002)
Underweight
BMI< 18.5
Normal weight
18.5BMI< 25
Overweight
25BMI< 30
Obese
BMI 30
Females 0.33 1.0 1.76 2.03
Males 0.00 1.0 1.07 1.69
The estimates are age-adjusted hazard ratios from a survival re-
gression model. OA is deﬁned as self-reported physician-diag-
nosed OA. BMI¼weight/height2.
Table IV
Effects of age, sex, OA diagnosis and BMI category on HUI3 scores
in the CCHS (2001)
Regression coefﬁcient
Intercept 0.62
Age 12e19 0.30
Age 20e29 0.29
Age 30e39 0.29
Age 40e49 0.24
Age 50e59 0.20
Age 60e69 0.19
Age 70e79 0.15
Age 80þ (ref) 0.00
Sex e male 0.06
Sex e female (ref) 0.00
OA diagnosis e yes 0.10
OA diagnosis e no (ref) 0.00
BMI 0e18.4 0.05
BMI 18.5e24.9 0.08
BMI 25.0e29.9 0.06
BMI 30þ (ref) 0.00
BMI (0e18.4)Sex (M) 0.07
BMI (18.5e24.9)Sex (M) 0.06
BMI (25.0e29.9)Sex (M) 0.03
BMI (30þ)Sex (ref) 0.00
OA (yes)Sex (M) 0.04
OA (no)Sex (ref) 0.00
HUI3¼Health Utilities Index Mark 3.
307Osteoarthritis and Cartilage Vol. 18, No. 3In POHEM-OA, HRQL (measured by HUI3) is predicted
by OA, age, sex and BMI, using a tobit model49 (Table IV).
The effects of OA and BMI on HUI3 were different in men
and women. This difference in effects is captured by the in-
teractions between BMI and sex and between OA and sex
that were highly signiﬁcant. The average impact of OA diag-
nosis is to decrease HUI3 score by 0.10 in women and 0.14
in men. Age has a negative effect on HUI3 and women
have, on average, lower HUI3 scores than men. Model ﬁt
was adequate, as suggested by the estimated error term
which was very similar in the reduced and saturated models
(data not shown). The likelihood ratio test was signiﬁcant,
indicating that additional interaction terms might improve
the ﬁt of the model, but this test is less informative when
the sample size is very large.
Discussion
This article describes the methodology and key parame-
ters for a population-based simulation model of OA in Can-
ada, with a focus on OA incidence and its impact on quality
of life. Most of the input parameters have been derived from
the Canadian Census and vital statistics databases, national
surveys, administrative data in British Columbia, and the
health literature. Advanced statistical methods have been
used to derive time-to-event distributions and the relation-
ships between the variables. Model calibration ensures that
the simulated incidence rates agree with the observed rates.
The model uses the POHEM platform, a state-of-the-art mi-
crosimulation tool that can simulate a dynamic population as it
changes over time, as opposed to modeling a ﬁxed cohort or
a stationary population. Events are modeled in continuous
time and there is no limit on the number of events that can be
simulated. An important feature of POHEM-OA is the transpar-
ency of the model. The structure of the model, parameter
values, and sourcesof data are publicly available. Assumptions
and limitations of the model are acknowledged and discussed.OA incidence rates in POHEM-OA are higher than those
estimated by Oliveria et al. for radiographic and symptomatic
OA of the knee, hip and hand, derived from an administrative
database in the US50. This is epidemiologically plausible
since our deﬁnition included all OA sites and did not require
radiographic conﬁrmation. At the same time, our rates are
lower than published incidence rates of self-reported ‘‘arthri-
tis or rheumatism’’ in Canada51. Direct comparisons between
the clinical and administrative diagnosis of OA are scarce.
Harrold et al.53 found a positive predictive value of 62% in
the US using medical records as a gold standard. In our pre-
vious validation study, the administrative deﬁnition of OA had
sensitivity around 30% and speciﬁcity over 90% against a di-
agnosis based on clinical and radiographic criteria52.
The simulation-derived estimates of baselineOA prevalence
in POHEM-OA are higher than those directly obtained from ad-
ministrative data45. The most likely reason is the tendency for
administrative data to underestimate OA prevalence due to in-
sufﬁcient run-in time. This tendency has been previously dem-
onstrated in our database45. Our estimates of baseline
prevalence are consistent with the most recent incidence rates
observed in the data. Although our previous study using the BC
databasesuggestedan increase inage-standardized incidence
rates of OA among women between 1996 and 2003, data on
long-term trends inOA incidencearenotavailable3.For this rea-
son, and to simplify the analysis, we assumed that the age/sex-
speciﬁc incidence rates in the past were constant. Baseline
prevalence in our model is overestimated if the incidence rates
were lower prior to baseline (i.e., if there was an increasing
trend), and underestimated if the incidence rates were higher,
but the difference is very unlikely to be substantial.
The risk of developing OA in POHEM-OA is determined by
age, gender and BMI. The effect of BMI on the OA incidence
rate was estimated from a longitudinal population survey in
Canada using self-reported physician-diagnosed OA. Com-
parative data for a similar deﬁnition of OA are not available.
In a studyof radiographic kneeOAbyFelsonet al.41 in theFra-
mingham cohort, the age-adjusted odds ratios in the highest
and second highest quintiles of height-adjusted weight were
2.07 and 1.44, respectively, for women, and 1.51 and 1.00, re-
spectively, for men. Given the differences in deﬁnitions and
methodology between the two studies, the results are remark-
ably similar to the hazard ratios from our model (Table III).
The effects of age, sex and OA on HUI3 were estimated
from the CCHS, a large national survey in Canada. Com-
parative population data for a similar deﬁnition of OA are
not available. Schultz and Kopec54 previously estimated
the overall effect of ‘‘arthritis and rheumatism’’ on HUI3 at
0.09 using data from the 1996/7 NPHS and adjusting for
co-morbidity. Similar to the current study, the effect was
stronger in men. In a graphical analysis, our model pre-
dicted HUI3 scores observed in a different CCHS cycle
with acceptable accuracy (data not shown).
While the results of preliminary validation are promising,
there is a need for more validation studies. Future validation
will include re-evaluation of the current input parameters,
comparisons of model output with the actual trends
observed in administrative and survey data from several
Canadian provinces, and stochastic sensitivity analyses.
The deﬁnition of OA adopted in our model is useful from
a healthcare utilization perspective but it has clear limita-
tions. Our model is unable to distinguish between different
OA sites, which limits its ability to model heterogeneous ef-
fect of risk factors on OA incidence. In terms of modeling
the impact of OA on quality of life, many cases of symptom-
atic or even disabling OA remain undiagnosed. The effect of
our OA deﬁnition on the estimates of disease burden in
308 J. A. Kopec et al.: A microsimulation model of osteoarthritisPOHEM-OA will be evaluated in a sensitivity analysis. Mod-
eling joint pain and other symptoms in the population, as
opposed to physician-diagnosed OA, might be a potentially
useful alternative in future studies.
We acknowledge that the values of the speciﬁc parame-
ters in POHEM-OA are potentially subject to criticism and
may need to be modiﬁed as new and better data become
available. Different studies may produce different estimates
of the incidence, prevalence, relative risk, or health impact
of OA. A limitation of the current version of POHEM-OA is
that it does not include other factors that may potentially af-
fect the incidence of OA, such as geographic region, race,
socio-economic status, injury, physical activity, or family
history of OA2. Data on the distribution of these factors in
the population, changes over time, and causal effects on
the risk of OA are insufﬁcient at this time. Projections of dis-
ease incidence and prevalence from our model may be in-
accurate if there are temporal changes in the distribution of
these factors, as well as other and unknown risk factors for
OA. This limitation can be minimized by introducing a cor-
rection for trend in incidence rates based on historical
data. Furthermore, the effect of BMI on OA incidence in
the model is derived from data on self-reported physician-
diagnosed OA of any joint. While this effect may be attenu-
ated due to unavoidable misclassiﬁcation of the disease, it
is based on the best Canadian data currently available.
At present, POHEM-OA does not contain any parameters
describing the effects of speciﬁc interventions on changes
in health behaviors, such as diet or healthcare utilization, in
different population groups. Implementing such parameters
would allow amore realistic simulation of the impact of health
policies across various segments of the population. Although
the available data are limited, we intend to incorporate behav-
ioral effects into future versions of the model.
Despite its limitations, the current model can inform policy
by providing information not directly available from epidemio-
logical studies. Its main purpose is to study the effects of
changes in the distribution of risk factors for OA on the future
burden of this disease in a dynamically changing population.
Current policy analyses typically make simplifying assump-
tions about the population under study and the effects of
health interventions at the population level15,16. In particular,
standard methods of calculating attributable fraction usually
assume that the risk factor is eliminated and that the underly-
ing population is static. In addition, such methods generally
do not consider the impact of disease on quality of life14.
The current model can be used to project the future burden
of OA in Canada while taking into account trends in popula-
tion aging and obesity prevalence. For example, we have re-
cently applied the model to compare different scenarios for
future OA incidence rates in terms of their impact on health-
adjusted life expectancy (HALE) inCanada55. Preliminary re-
sults show that if new cases ofOAdue to excessweight could
be avoided, average HALE would improve by 2e4 months
and the gain would be somewhat greater in women. Another
example is the use of themodel to analyze the relative contri-
butions of aging and obesity to the projected increase in the
number of persons with OA56.
In conclusion, we have developed the ﬁrst population-
based microsimulation model of OA. We hope the model
will provide a benchmark for the synthesis of quantitative
data on the epidemiology and population health impact of
OA. We expect to be able to improve the model as gaps in
knowledge are addressed in future studies. While the initial
results from this model will have to be taken with caution,
the conﬁdence in the results will increase as the validity of
the model is further conﬁrmed under a variety of conditions.Conﬂict of interest
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Population parameters
Tables A1eA7 shows the distribution of key POHEM-OA
variables in the CCHS. These tables include all CCHS re-
spondents. Weighted data reﬂect the distribution in the Ca-
nadian household population. Data in Tables A8eA10 are
shown for illustration purposes. The estimates are rounded
and shown for selected ages and/or years only. When run-
ning POHEM, more precise estimates for all ages and years
are used.
Table A1
Distribution of the CCHS (2001) population by province of residence
Province Sample Population (weighted)N % N %Newfoundland 3,870 3.0 461,104 1.8
Prince Edward Island 3,651 2.8 116,327 0.5
Nova Scotia 5,319 4.1 787,972 3.1
New Brunswick 4,996 3.8 634,264 2.5
Quebec 22,012 16.8 6,216,722 24.1
Ontario 39,278 30.0 9,877,292 38.3
Manitoba 8,470 6.5 907,494 3.5
Saskatchewan 8,009 6.1 805,993 3.1
Alberta 14,456 11.0 2,481,568 9.6
British Columbia 18,302 14.0 3,421,671 13.3
Yukon and NWT 2,517 1.9 76,928 0.3Total 130,880 100.0 25,787,334 100.0NWT¼Northwest Territories.
Table A2
Distribution of the CCHS (2001) population by age group
Age group Sample Population (weighted)N % N %12e14 6,476 4.9 1,186,119 4.6
15e19 11,081 8.5 2,131,999 8.3
20e24 7,584 5.8 2,112,568 8.2
25e29 8,742 6.7 2,006,021 7.8
30e34 10,281 7.9 2,158,989 8.4
35e39 12,447 9.5 2,587,642 10.0
40e44 12,886 9.8 2,707,970 10.5
45e49 11,388 8.7 2,369,433 9.2
50e54 10,255 7.8 2,051,946 8.0
55e59 8,355 6.4 1,585,225 6.1
60e64 7,152 5.5 1,244,611 4.8
65e69 6,842 5.2 1,151,556 4.5
70e74 6,360 4.9 1,003,709 3.9
75e79 5,237 4.0 740,459 2.9
80þ 5,794 4.4 749,088 2.9
Total 130,880 100.0 25,787,335 100.0
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Distribution of the CCHS (2001) population by sex
Sex Sample Population (weighted)N % N %Male 60,514 46.2 12,714,150 49.3
Female 70,366 53.8 13,073,184 50.7Total 130,880 100.0 25,787,335 100.0Table A4
Distribution of the CCHS (2001) population by level of education
Education Sample Population (weighted)N % N %Less than secondary 44,338 33.9 7,594,745 29.5
Secondary 22,860 17.5 4,758,801 18.5
Some post-secondary 9,832 7.5 2,107,601 8.2
Post-secondary grad. 52,586 40.2 11,108,414 43.1
Not stated 1,264 1.0 217,774 0.8Total 130,880 100.0 25,787,335 100.0Table A5
Distribution of the CCHS (2001) population by income
Income Sample Population (weighted)N % N %None 5,704 4.4 1,327,650 5.1
<$15,000 34,229 26.2 6,141,039 23.8
$15,000e29,999 28,061 21.4 5,281,922 20.5
$30,000e49,999 24,220 18.5 5,191,844 20.1
$50,000e79,999 13,578 10.4 2,945,634 11.4
$80,000 or more 4,524 3.5 1,081,049 4.2
Not applicable 6,476 4.9 1,186,119 4.6
Not stated 14,088 10.8 2,632,077 10.2Total 130,880 100.0 25,787,334 100.0Table A6
Distribution of the CCHS (2001) population by BMI
BMI Sample Population (weighted)N % N %Underweight (BMI< 20) 6,040 4.6 1,473,150 5.7
Acceptable (BMI 20e24.9) 35,404 27.1 7,944,017 30.8
Overweight (BMI 25) 44,730 34.2 8,882,610 34.4
Not applicable 42,866 32.8 7,189,595 27.9
Not stated 1,840 1.4 279,962 1.2Total 130,880 100.0 25,787,334 100.0Table A7
Distribution of the CCHS (2001) population by the Health Utilities
Index Mark 3 (HUI3)
HUI3 Sample Population (weighted)N % N %<0.0 799 0.6 138,751 0.5
0.0e0.099 888 0.7 151,656 0.6
0.1e0.199 1,082 0.8 180,531 0.7
0.2e0.299 1,916 1.5 308,631 1.2
0.3e0.399 2,979 2.3 501,022 1.9
0.4e0.499 2,428 1.9 427,027 1.7
0.5e0.599 2,438 1.9 425,220 1.7
0.6e0.699 6,031 4.6 1,096,935 4.3
0.7e0.799 8,545 6.5 1,578,011 6.1
0.8e0.899 12,469 9.5 2,388,627 9.3
0.9e0.999 57,344 43.8 11,504,065 44.6(continued)Table A7 (continued )HUI3 Sample Population (weighted)N % N %1.0 32,272 24.7 6,855,037 26.6
Missing 1,689 1.3 231,822 0.9Total 130,880 100.0 25,787,334 100.0Table A8
Baseline prevalence (%) of OA for selected ages
Age Men Women20 0.1 0.1
30 0.9 0.9
40 2.9 3.0
50 7.9 8.8
60 16.8 22.2
70 29.2 39.8
80 43.0 56.1
90 54.8 68.2Table A9
Reference incidence rates of OA per 1000 person-years for
selected ages
Age Men Women20 0.5 0.6
30 1.4 1.2
40 3.5 3.1
50 6.8 8.2
60 13.1 16.4
70 18.3 23.2
80 23.8 29.9
90 28.1 31.1Table A10
Mortality rates in Canada per 1000 population for selected ages
and years (including projected rates)
Age 2001 2006 2011 2016 2021Women
20 0.26 0.25 0.24 0.24 0.23
30 0.35 0.34 0.33 0.32 0.31
40 0.69 0.68 0.66 0.64 0.63
50 1.78 1.74 1.67 1.65 1.61
60 4.70 4.58 4.47 4.36 4.25
70 12.28 11.98 11.69 11.40 11.12
80 31.03 30.26 29.52 28.79 28.08
90 73.83 72.01 70.23 68.50 66.81Men
20 0.59 0.52 0.49 0.47 0.45
30 0.73 0.70 0.66 0.63 0.60
40 0.84 0.80 0.76 0.72 0.69
50 2.07 2.00 1.87 1.78 1.69
60 5.73 5.45 5.19 4.94 4.70
70 14.43 13.73 13.07 12.44 11.84
80 34.41 32.75 31.17 29.67 28.24
90 81.33 77.40 73.67 70.11 66.73INCIDENCE MODELThe following steps describe the basic algorithm for de-
termining when OA occurs in the microsimulation:
(1) POHEM selects a record from the CCHS database in
the simulation start year (2001).
(2) At each birthday in the person’s simulated life, annu-
alized hazard h is calculated as: h¼ h0RR. In this
310 J. A. Kopec et al.: A microsimulation model of osteoarthritisequation h0 is the age/sex-speciﬁc OA incidence rate
for persons with normal BMI estimated from BCLHD
rates using calibration methods (Table A9 in the Ap-
pendix), and RR is the relative risk (hazard ratio) of
OA based on person’s BMI category (Table III in the
manuscript).
(3) A random number u between 0 and 1 is generated
and the time of event (in years) is estimated as t¼ln
(1 u)/h. If t 1 no event occurs during the year.
Note that competing events, such as death, could
censor this event.
(4) Steps 2e3 are repeated at every subsequent birthday
until the person develops OA or dies.
(5) Steps 1e4 are repeated for every individual record in
our start-up database.BMI MODELThe BMI model is part of the POHEM software and was
developed by Statistics Canada using biannual data from
the longitudinal NPHS 1996e2004. The model predicts cur-
rent BMI within 14 groups deﬁned by BMI category and age,
separately for men and women, based on BMI history and
other covariates, such as region of residence, income and
education. The response variable is change in BMI com-
pared to 2 years prior, treated as a continuous, normally dis-
tributed variable. The model includes the most recent BMI
value and up to three prior changes in BMI. The model
can be presented in a simpliﬁed form as:
DBMIt ;tþ2 ¼ aþ b1BMIt þ b2DBMIt2;t þ b3DBMIt4;t2
þ b4DBMIt6;t4 þ b5Incomet6
þ b6Educationt6 þ b7Regiont6
In this equation, DBMIi;j ¼ BMIj  BMIi is the difference in
BMI between time i and time j.
There are 112 regression equations arising from 28 strata
(modeling groups) generated by the 14 ageBMI cate-
gories and the sex variable (male and female). Within
each stratum, there are four models, depending on the
number of prior BMI values used.References
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